PROLOR Biotech is a clinical-stage biopharmaceutical company applying unique technologies, including patented CTP technology, to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. Its CTP technology is applicable to virtually all proteins.

The company recently reported positive results from a preclinical toxicology study designed to determine the safety and tolerability of PROLOR’s proprietary long-acting reversible-pegylation technology (RPeg). The results of the study showed that RPeg was safe and well-tolerated at high doses following repeated administration in laboratory rats.

The RPeg platform has been utilized to develop PROLOR’s preclinical drug candidate MOD-6030, a GLP-1/Glucagon dual receptor agonist peptide in development for the dual indications of obesity and type 2 diabetes. The company believes that RPeg can potentially be applied to a range of peptide and small molecule drugs to increase their duration of effectiveness. It is expected to be especially well suited for use with drugs that must cross the blood-brain barrier.

The positive results of the study will certainly move forward the development of the company’s MOD-6030 drug candidate. But even more importantly, the results reinforce the use of the RPeg platform as a safe and well-tolerated platform for the development of a wide range of longer-acting peptides and drugs.

For more information about PROLOR Biotech and its proprietary RPeg platform, please visit www.prolor-biotech.com

Let us hear your thoughts below: